The product safety sphere is fast moving and without hands-on monitoring, any changes to the global regulatory framework can easily be missed. This is why we're here to lend a hand by keeping you abreast of any CSR, technological or regulatory changes that may impact your business.
These key updates will help you to adjust your business strategies, ensure compliance and avoid the potential for enforcement action. We will share our experience and insight from both UK and global perspectives and bring you guest writers from across the industry.
To help you navigate to your area of interest, the content is divided into the subcategories: chemicals, cosmetics, CSR, ESR and D&I, food and drink, general consumer product issues, industrial products, life sciences, new technologies, vehicles.
Product innovation – highlighted by COVID-19 vaccines – continues to make headline news. As the adoption of emerging technologies gathers pace, regulation is evolving to reflect this changing environment. In this report, we consider developments in the product safety and product liability sphere, and provide an overview of the topics and trends that are likely to impact corporates and their insurers in the months ahead.
Read moreFrom To
Subscribe to our latest updates, reports and events.
SubscribeShowing 1 - 10 of 39
Sort by
Blog 26/01/2023
In this blog, we explore how developments in technology have created new types of product liability and safety risks and given rise to new categories of damage. We also examine developments in the mechanisms for claiming damages.
Blog 13/01/2023
It is undeniable that the way consumers purchase their products and engage with services on the internet has changed substantially since times past. The modern consumer has global buying power, and suppliers must adapt in order to meet this consumer demand. This change in consumer behaviour has brought both benefits, but also introduced legal risks that have required careful consideration by regulators and legislators alike.
Blog 12/01/2023
In the last ten years there has been a significant growth in the use of collective redress or representative actions ('group litigation'), a legal mechanism which may stop or prevent unlawful business practices that affect multiple claimants or compensate them for harm caused by these practices, within the EU and UK.
Blog 02/11/2022
On 28 September 2022, the European Commission (EC) published its much-awaited proposals to significantly reform the EU Product Liability Directive (85/374/EEC) (PLD). The existing PLD came into force in July 1985 and has been the mainstay law governing redress for defective products across the EU. The legislation imposes a strict liability for defective products which have caused a loss to consumers.
Blog 14/10/2022
Environmental, social and governance (ESG)-type obligations are increasingly imposed on actors in the modern product supply chain. Such obligations impact all stages of the product lifecycle and additionally impose subject-matter specific reporting obligations on companies in respect of these matters.
Blog 12/10/2022
In an era of growing eco awareness an increasing number of companies are making environmental and sustainability claims about their practices, products and services. However, a recent international analysis of websites found that 40% of green claims made online could be misleading.
Blog 16/06/2022
The European Commission’s public consultation on the EU Cosmetics Products Regulation to run until 21 June 2022.
Blog 29/04/2022
On 24 March 2022, EU legislators reached political agreement on the long awaited Digital Markets Act (DMA) which seeks to regulate ‘gatekeeper’ technology giants and a promote fair and open digital market.
Blog 22/04/2022
Since the UK’s exit from the European Union, the Medicines and Healthcare products Regulatory Agency (MHRA) has provided guidance on the regulation of medical devices and the requirements for their entry into the UK market.
Blog 21/04/2022
The long awaited regulation on Health Technology Assessment (HTA), adopted on 13 December 2021 and published in the EU Official Journal on 22 December 2021, is a deliverable of the EU Pharmaceutical Strategy that aims to revolutionise patient access to vital and innovative technologies.
